Last 153.40 INR
Change Today -5.20 / -3.28%
Volume 497.9K
PNCB On Other Exchanges
Symbol
Exchange
Natl India
As of 6:06 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

panacea biotec ltd (PNCB) Snapshot

Open
159.00
Previous Close
158.60
Day High
164.15
Day Low
152.30
52 Week High
09/22/14 - 219.35
52 Week Low
01/30/14 - 88.60
Market Cap
9.4B
Average Volume 10 Days
245.1K
EPS TTM
-18.31
Shares Outstanding
61.3M
EX-Date
09/19/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PANACEA BIOTEC LTD (PNCB)

Related News

No related news articles were found.

panacea biotec ltd (PNCB) Related Businessweek News

No Related Businessweek News Found

panacea biotec ltd (PNCB) Details

Panacea Biotec Limited, a health management company, researches and develops, manufactures, and markets pharmaceuticals, biopharmaceuticals, vaccines, and natural/indigenous products in India and internationally. Its product portfolio includes prescription products in various therapeutic areas, including pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care and vaccines. The company has collaboration agreements with The Institute for Translational Vaccinology (Intravacc), the Netherlands; JSC Binnopharm Inc., Russia; National Institute of Immunology, India; Dr. Reddy’s Laboratories Limited; PT BioFarma, Indonesia; and Kremers Urban Inc., as well as strategic alliance with Apotex Inc. Panacea Biotec Limited was founded in 1984 and is based in New Delhi, India.

2,750 Employees
Last Reported Date: 08/27/14
Founded in 1984

panacea biotec ltd (PNCB) Top Compensated Officers

Managing Director, Director and Member of Sta...
Total Annual Compensation: 7.2M
Joint Managing Director and Whole-Time Direct...
Total Annual Compensation: 6.0M
Joint Managing Director and Director
Total Annual Compensation: 5.6M
Founder and Chairman
Total Annual Compensation: 7.2M
Director of Operations & Projects, Whole-Time...
Total Annual Compensation: 2.5M
Compensation as of Fiscal Year 2014.

panacea biotec ltd (PNCB) Key Developments

Panacea Biotec Ltd. Announces Collaboration with International Pharmaceutical Company for the Development and Supply of an Immunosuppressant Generic Product in USA

Panacea Biotec Ltd. has entered into collaboration with International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA. The collaboration has been established on December 23, 2014, for the research, development and subsequent ANDA submission by Panacea Biotec for a generic immunosuppressant drug. Under the terms of the agreement, the company shall receive an upfront Research Fee, as well as milestone payments linked with the development of the product. Upon commercialization of the product, Panacea Biotec shall be responsible for manufacturing and supply of the product to the partner company, while the partner would be responsible for front end sales and distribution in U.S.A. Both companies have agreed on a hybrid model of transfer price and profit share at a pre-agreed ratio.

Panacea Biotec Ltd. Enters into Collaboration with Rising Pharmaceuticals

Panacea Biotec Ltd. said it had entered into a collaboration with Rising Pharmaceuticals, Inc. The collaboration has been established for an oral controlled release product utilizing the company's platform oral dug delivery technology. The dossier for the product is currently under review by FDA. Under the terms of the agreement, the company shall receive an upfront research fee on signing as well as a milestone payment on approval of the product by FDA. Upon commercialization of the product, both companies shall share the profits at a pre-agreed ratio.

Panacea Biotec Announces Strategic Alliance with Apotex Inc

Panacea Biotec announced that it has entered into a strategic alliance with Apotex Inc. The strategic alliance was initially established for a drug delivery based drug for which Panacea Biotec had received research fees and the product development is progressing on priority. Panacea Biotec and Apotex have now further expanded the scope of the collaboration by including a second drug delivery based product to the collaboration. Both the products have been developed using Panacea Biotec's proprietary platform nanoparticle, liposomal and microparticle drug delivery systems. The current sales of the innovator products are to the tune of about USD 1 billion. In addition to an upfront and milestone research fee payments from Apotex: Panacea Biotec shall receive a share of the development cost and profit post commercialization of the products shall be shared at a pre-agreed ratio between both companies. Both companies intend to expand the scope of the alliance by adding new drug delivery based complex generic products to the collaboration. Panacea Biotec shall undertake product development and shall manufacture and supply the products to Apotex, while Apotex shall be responsible for regulatory affairs. Hatch Waxman litigation and commercialization activities in the territories.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PNCB:IN 153.40 INR -5.20

PNCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,385 GBp 0.00
Johnson & Johnson $104.59 USD +0.31
Novartis AG SFr.92.35 CHF -1.20
Pfizer Ltd/India 2,015 INR -30.55
Sanofi India Ltd 3,431 INR +68.45
View Industry Companies
 

Industry Analysis

PNCB

Industry Average

Valuation PNCB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PANACEA BIOTEC LTD, please visit www.panacea-biotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.